1. Trimodality Therapy for Lung Cancer With Chest Wall Invasion: Initial Results of a Phase II Study 
Koji Kawaguchi, MD, Kohei Yokoi, MD, Hiroshi Niwa, MD, Yasuhisa Ohde, MD, Shoichi Mori, MD, Sakae Okumura, MD, Satoshi Shiono, MD, Hiroyuki Ito, MD, Motoki Yano, MD, Kikuo Shigemitsu, MD, Yoshinori Hiramatsu, MD, Jiro Okami, MD, Hiroshi Saito, MD 
The Annals of Thoracic Surgery 
Volume 98, Issue 4, Pages (October 2014)
DOI: /j.athoracsur
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
A schematic diagram depicting the Central Japan Lung Study Group (CJLSG) (CDDP = cisplatin; NSCLC = non-small cell lung cancer; PS = performance status; RT = radiation therapy; VNR = vinorelbine.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
The (A) overall and (B) progression-free survival curves from the day of the registration. The 2-year overall and progression-free survival rates were 85% and 71%, respectively.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
The overall survival curves of patients stratified by their response to the induction chemoradiotherapy. No significant difference was seen between the two groups (p = 0.263), although patients with downstaged disease (solid line) seemed to have better survival than those who did not have downstaged disease (dashed line).
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2014 The Society of Thoracic Surgeons Terms and Conditions